Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Pfizer Germany launches Dupuytren’s contracture awareness campaign

Website supports company's novel, first-in-class, biologic Xiapex

Pfizer Germany online Dupuytren's campaign

Pfizer Germany has launched an online campaign to raise awareness of the progressive connective tissue disorder Dupuytren's contracture.

Based around the dupuytren-loesen.de website it offers patients and their families information on the disorder, including a self-test checklist, patient stories and a series of questions to ask their doctor.

Pfizer's novel, first-in-class, biologic Xiapex (collagenase clostridium histolyticum) was approved in Europe last March to treat Dupuytren's contracture and launched in a number of European countries, including Germany, Spain and the UK, during 2011.

The pharma company said its new German online portal would help visitors to understand the disease and give them an over view of the treatment options, with and with surgery, that are available.

Dupuytren's contracture results in a patient's fingers bending towards the palm of their hand, traditionally requiring surgery to straighten them.

The condition most commonly occurs in white Europeans, affecting up to 20 per cent of men over 60 and up to 20 per cent of women over 80.

21st February 2012

From: Marketing

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics